Nebius does not pass the ethical screen. The binding factor is interest/revenue 6.0%.
Nebius Group N.V.
NBIS · Nasdaq · USD · Market cap $43.7B · 1,543 employees
Nebius Group N.V., a technology company, engages in building full-stack infrastructure to service the global AI industry in the United States, the United Kingdom, and internationally.
FAIL · Does not pass the screenPrice as of 3 Nov 2026Daily close, not a live quote
Screened 2026-11-03 · the tape above runs as of 16:09 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price151.64 USD at the 3 Nov 2026 close
- Fair valueUnder review: our model's value is 2.14x the price, above our 2.00x limit.
- Our regime readMarkdown, as of 3 Nov 2026
- Ethical screenDoes not pass
- OptionsOpen interest leans to puts (put/call 2.28)
- Last reviewed3 Nov 2026 (1 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: range not available (screen dated 2026-11-03).
- Trend Markdown
- Insiders insiders bought, latest filing 2026-10-29
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 2.28, read 2026-10-30
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its markdown label.
Nebius Group N.V. holds its Markdown at $151.64. Consolidating, no directional conviction, held for 36 days.
| Phase | Markdown · caution |
| Quantitative state | Consolidating, no directional conviction, held for 36 days |
| Price at the screen | $151.64 |
| Valuation | 134.37 trailing · -47.80 forward price to earnings |
| Values screen | FAIL · score 93.7 |
| Beta | 1.46 |
Five Screens, Shown in Full
Does not pass. Interest/revenue 6.0%
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 9.45% | Below 33% | Interest-bearing debt is just 9.4% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 7.13% | Below 33% | Cash held in interest-bearing accounts and securities is 7.1% of assets, under the one-third limit. | Pass |
| Receivables | 0.00% | Below 49% | Money owed to the company is 0.0% of assets, under the 49% limit. | Pass |
| Revenue purity | 6.00% | Below 5% | 6.0% of revenue comes from non-compliant sources, over the 5% line. | Fail |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Falls Short, in Plain English
Nebius does not pass the ethical screen. The binding factor is interest/revenue 6.0%.
Read as at 2026-11-04. It updates when the underlying figures move, and past reads are kept below.
Nebius clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 9%, inside the ~33% line, and almost none of its income is interest, so it passes.
Earlier reads, kept as written. The ethical profile is tracked over time, not overwritten.
Follow this verdict
Get an email when NBIS's ethical verdict changes
Today NBIS does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Fair value under review. Our model's value is 2.14x the price, above our 2.00x limit. We show no fair value, margin of safety or value read built on it until the review clears.
How a fair value is estimated: discounted cash flow (DCF).
The Street's RangeThird-party analyst targets: 20 covering, consensus Buy. The average target sits +99% from the screen price.
Where our models see it going: no fair-value estimate yet, range not available, dated to the 2026-11-03 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words| Forward P/E | -47.8x |
| Trailing P/E | 134.4xexpensive: the price assumes strong growth ahead |
| EPS, trailing | 1.28 |
| EPS, forward | -3.60 |
| Revenue growth | +454.0%growing very fast |
| Profit margin | 3.1%barely profitable |
| Return on equity | 0.6%a modest return on shareholder capital |
| FCF yield | -22.02% |
| Debt to equity | 0.99moderate, manageable leverage |
| Current ratio | 4.03comfortably covers its short-term bills |
| Beta | 1.46moves a little more than the market |
| Short interest, float | 0.20% |
| 52-week range | 73.52 - 299.86 |
| Market cap | $43.7B |
| Employees | 1,543 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it already moves more than the market on an average day; its business and earnings are exposed to Netherlands and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeNBIS trades on Nasdaq (the company is based in Netherlands). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 1.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 10% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 305%. Our forward projection puts the odds of a 10% gain over the next month near 51%. The street (13 analysts) rates it buy, with a mean price target of $231. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 10% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 305%. Our forward projection puts the odds of a 10% gain over the next month near 51%. The street (13 analysts) rates it buy, with a mean price target of $231. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 18.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 10% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 305%. Our forward projection puts the odds of a 10% gain over the next month near 51%. The street (13 analysts) rates it buy, with a mean price target of $231.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 5% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 305%. Our forward projection puts the odds of a 10% gain over the next month near 51%. The street (13 analysts) rates it buy, with a mean price target of $231.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 20.6% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 89% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 305%. Our forward projection puts the odds of a 10% gain over the next month near 51%. The street (13 analysts) rates it buy, with a mean price target of $231.
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 89% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 305%. Our forward projection puts the odds of a 10% gain over the next month near 51%. The street (13 analysts) rates it buy, with a mean price target of $231.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 7.8% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 89% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 305%. Our forward projection puts the odds of a 10% gain over the next month near 51%. The street (13 analysts) rates it buy, with a mean price target of $231. Since the last review it entered the Tech 100.
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 0.5% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 89% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 305%. Our forward projection puts the odds of a 10% gain over the next month near 51%. The street (13 analysts) rates it buy, with a mean price target of $231.
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 3.9% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 89% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 305%. Our forward projection puts the odds of a 10% gain over the next month near 51%. The street (13 analysts) rates it buy, with a mean price target of $231.
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 89% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 305%. Our forward projection puts the odds of a 10% gain over the next month near 51%. The street (13 analysts) rates it buy, with a mean price target of $231.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- FuelCell Energy Sinks 12% Despite Completing $49 Million Export-Import Bank Financing; Bloom Energy Tumbles 10%, Plug Power Falls 4% Yahoo Finance · 5d ago
- Best Momentum Stocks to Buy for October 30th Yahoo Finance · 5d ago
- Why Nebius Stock Fell 26% in a Month, and What It Means for Investors Yahoo Finance · 5d ago
- Nebius Group announces date of third quarter 2026 results and conference call Yahoo Finance · 5d ago
- Satya Nadella Just Took a Shot at Oracle and CoreWeave Yahoo Finance · 5d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-29 | Grimme Arne | Dir | P - Purchase | 148 | $25,074 |
| 2026-10-27 | Grimme Arne | Dir | P - Purchase | 353 | $57,740 |
| 2026-10-22 | Grimme Arne | Dir | P - Purchase | 770 | $122,438 |
| 2026-10-19 | Grimme Arne | Dir | P - Purchase | 148 | $25,159 |
| 2026-10-15 | Grimme Arne | Dir | P - Purchase | 296 | $50,317 |
| 2026-10-12 | Boroditsky Marc | Chief Revenue Officer | S - Sale+OE | 7,000 | $1,478,610 |
| 2026-10-05 | Nave Ophir | COO | S - Sale | 500,000 | $117,765,468 |
| 2026-10-01 | Korolenko Andrey | Chief Infrastructure Officer | S - Sale | 29,090 | $6,811,714 |
| 2026-10-01 | Shtan Danila | CTO | S - Sale | 14,546 | $3,406,091 |
| 2026-10-01 | Volozh Arkadiy | CEO, 10% | S - Sale | 37,778 | $8,846,096 |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $186.10 | +14.1% | · | $1,141 | +14.1% |
| 2 months | $144.97 | +46.5% | · | $1,465 | +46.5% |
| 3 months | $108.04 | +96.6% | · | $1,966 | +96.6% |
| 6 months | $94.28 | +125.3% | · | $2,253 | +125.3% |
| 1 year | $52.51 | +304.5% | · | $4,045 | +304.5% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever NBIS does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.